Original Research
Published on 07 Nov 2025
Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)
in Pharmacology of Anti-Cancer Drugs
- 160 views